TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).

Inclusion Criteria: 1. Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or patients who meet the clinical diagnostic criteria for primary liver cancer; 2. Age ≥18 years at the time of HCC diagnosis; 3. Barcelona Clinic Liver Cancer (BCLC) stage C; 4. No prior systemic therapy for HCC (including chemotherapy, molecular targeted therapy, or immunotherapy); 5. Received treatment with tislelizumab and lenvatinib, with the interval between the first administration of the two drugs ≤1 week; 6. In the experimental group, TACE was performed within 3 months before or after treatment with tislelizumab and lenvatinib; 7. After TACE, patients received at least one cycle of combination therapy with tislelizumab and lenvatinib, including cTACE and DEB-TACE; 8. Child-Pugh class A5 to B7; 9. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1; 10. At least one measurable intrahepatic lesion according to RECIST 1.1 criteria. Exclusion Criteria: 1. Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma histological types; 2. Complete obstruction of the main portal vein with insufficient collateral compensation; 3. Uncontrollable ascites or hepatic encephalopathy; 4. Incomplete clinical data or missing essential information; 5. Presence of other primary malignant tumors in addition to the diagnosis of liver cancer; 6. Participation in other interventional studies prior to treatment; 7. Other conditions deemed unsuitable for inclusion by the investigators.